HAI for Intrahepatic Cholangiocarcinoma:
The Intera 3000 and floxuridine combined with systemic chemotherapy (CT) to treat patients with unresectable intrahepatic cholangiocarcinoma (IHC) has been shown to increase patient overall survival.
In a single arm, prospective Phase II clinical trial, HAI therapy with systemic chemotherapy was shown to:
- Provide median overall survival of 25.0 months (95%CI, 20.6-not reached), and the 1-year OS rate was 89.5% (95%CI, 80.2%-99.8%).
- Twenty-two patients (58%) achieved a partial radiographic response, and 32 patients (84%) achieved disease control at 6 months. Four patients had sufficient response to undergo resection, and 1 patient had a complete pathologic response.